Monoclonal antibodies for the period 1.1.-31.12.2027 + option year 2028 for the welfare region of North Ostrobothnia
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Official contract award notice for Monoclonal antibodies for the period 1.1.-31.12.2027 + option year 2028 for the welfare region of North Ostrobothnia in Finland. Contracting Authority: Pohjois-Pohjanmaan hyvinvointialue. Awarded Contractor: 2care4 ApS, filial (2821736-7)//Abacus Medicine A/S (DK28111576)//Amgen Aktiebolag, filial i Finland (1090790-9)//Astellas Pharma a/s (DK10888638)//AstraZeneca Oy (0196941-1)//BeOne Medicines I GmbH, Dutch Branch (826240136)//Daiichi Sankyo Nordics ApS (39371049)//Gilead Sciences Finland Oy (2151739-1)//GlaxoSmithKline Oy (0108378-4)//Incyte Biosciences Finland Oy (2614186-4)//Janssen-Cilag Oy (0922140-8)//Kyowa Kirin AB (556662-3038)//MSD Finland Oy (0101072-9)//Medical Valley Invest AB (SE556681710101)//Merck Oy (0200696-7)//Orifarm Oy (1479981-0)//Orion Oyj (1999212-6)//Oy Bristol-Myers Squibb (Finland) Ab (0107119-3)//Oy Eli Lilly Finland AB (0211069-2)//Recordati AB (SE 556620-8350)//Regeneron NL B.V. (NL861254570B01)//Roche Oy (0498521-4)//Sandoz A/S (DK-27744532)//Sanofi Oy. Business ID (Y-tunnus): 1048723-8. Award Value: 24.00 EUR.